Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350279 | 1.00 | TP53 (0.48) | TP53TSHRKDM4ETDP1KMT2A | |
| SCHEMBL6237516 | 1.00 | TP53 (0.48) | TP53TSHRKDM4ETDP1KMT2A | |
| SCHEMBL4195533 | 0.86 | KMT2A (0.59) | TDP1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL4195531 | 0.86 | KMT2A (0.59) | TDP1KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL1485846 | 0.85 | LMNA (0.43) | TSHRKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL27999259 | 0.85 | POLB (0.48) | TSHRTDP1KMT2AMEN1LMNA | |
| SCHEMBL1663456 | 0.83 | HCAR3 (0.55) | TP53TSHRKDM4ETDP1KMT2A | |
| SCHEMBL669563 | 0.83 | MAPK13 (0.61) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL669564 | 0.83 | MAPK13 (0.61) | KDM4EKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL7146207 | 0.82 | F2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| WO-2024088712-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2024-05-02 | — | — | WO | claimed |
| US-20230310380-A1 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | GLAZIER ALAN NEIL (US) | 2023-10-05 | — | — | US | claimed |
| US-8053585-B2 | Protecting group for carboxylic acids that can be photolyzed by visible light | CORNELL RESEARCH FOUNDATION, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-20110263652-A1 | Treatment and/or Prevention of Inner Ear Conditions by Modulation of a Metabotropic Glutamate Receptor | HOUSE EAR INSTITUTE (US) | 2011-10-27 | — | — | US | claimed |
| EP-2344151-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | claimed |
| US-7648993-B2 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY (US) | 2010-01-19 | — | — | US | claimed |
| US-20070243519-A1 | Protecting group for carboxylic acids that can be photolyzed by visible light | CORNELL RESEARCH FOUNDATION, INC. (US) | 2007-10-18 | — | — | US | claimed |
| EP-1392363-B1 | Use of mGLuR5 antagonists in the manufacture of a medicament in the treatment of Fragile X syndrome, Autism and Mental Retardation | UNIV BROWN RES FOUND (US) | 2006-09-20 | — | — | EP | claimed |
| US-6916821-B2 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY (US) | 2005-07-12 | — | — | US | claimed |
| US-6890931-B2 | Methods of treating disorders with group I mGluR antagonists | BROWN UNIVERSITY (US) | 2005-05-10 | — | — | US | claimed |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | BROWN UNIVERSITY RESEARCH FOUNDATION (BURF) (US) | 2004-04-08 | — | — | US | claimed |
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-29 | — | — | US | claimed |
| US-20020193285-A1 | Neuroprotectants formulations and methods | NEURON THERAPEUTICS | 2002-12-19 | — | — | US | claimed |
| US-6197820-B1 | METABOTROPIC GLUTAMATE RECEPTOR AGONIST/ANTAGONIST (S)-4-CARBOXYPHENYLGLYCINE (S-4CPG), POTENTLY AND SELECTIVELY INHIBITED GLUTAMATE RELEASE FROM GLIOMA CELLS AND THEREBY PREVENTED NEUROTOXICITY, INHIBIT RELEASE OF TOXIC LEVELS OF | UAB RESEARCH FOUNDATION | 2001-03-06 | — | — | US | claimed |
| WO-2000062771-A1 | USES OF PHENYLGLYCINE DERIVATIVES | THE UAB RESEARCH FOUNDATION (US) | 2000-10-26 | — | — | WO | claimed |
| EP-0832110-A1 | ANTIVIRAL PEPTOID COMPOUNDS | Novartis AG (CH) | 1998-04-01 | — | — | EP | claimed |
| WO-1996040759-A1 | ANTIVIRAL PEPTOID COMPOUNDS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | claimed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100539-A1 | Methods of treating neurological disorders with group I mGluR antagonists | GRM5, GRIK5, GRIN1 | TP53 4881/4885TSHR 1286/4885KDM4E 2848/4885 |
| US-20070243519-A1 | Protecting group for carboxylic acids that can be photolyzed by visible light | CYBA, ALDH3A1, HCCS | TP53 1747/4885TSHR 4627/4885KDM4E 2126/4885 |
| US-20040067978-A1 | Methods of treating disorders with Group I mGluR antagonists | GRM5, GRIK5, GRM2 | TP53 4883/4885TSHR 477/4885KDM4E 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.